4.6 Article

Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study

Journal

FRONTIERS IN ONCOLOGY
Volume 12, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2022.875489

Keywords

ovarian cancer; second primary malignancies; competing risk model; nomogram; SEER database

Categories

Funding

  1. Natural Science Foundation of China [82173612, 82173613]
  2. Shanghai Rising-Star Program [21QA1401300]
  3. Shanghai Municipal Natural Science Foundation [22ZR1414900]
  4. Three-year Action Program of Shanghai Municipality for Strengthening the Construction of Public Health System [GWV-10.1-XK05]
  5. Shanghai Municipal Science and Technology Major Project [ZD2021CY001]

Ask authors/readers for more resources

This study aimed to characterize the clinical features of early-stage ovarian cancer survivors with second primary malignancies and provided a prediction tool for personalized risk assessment. The results showed that several factors, including age, race, histologic subtypes of OC, lymph node examination, and radiotherapy, were significantly associated with an elevated risk of developing SPMs. The proposed nomogram demonstrated clinical utility in identifying patients with different risks of SPMs.
PurposeThis study aimed to characterize the clinical features of early-stage ovarian cancer (OC) survivors with second primary malignancies (SPMs) and provided a prediction tool for individualized risk of developing SPMs. MethodsData were obtained from the Surveillance, Epidemiology and End Results (SEER) database during 1998-2013. Considering non-SPM death as a competing event, the Fine and Gray model and the corresponding nomogram were used to identify the risk factors for SPMs and predict the SPM probabilities after the initial OC diagnosis. The decision curve analysis (DCA) was performed to evaluate the clinical utility of our proposed model. ResultsA total of 14,314 qualified patients were enrolled. The diagnosis rate and the cumulative incidence of SPMs were 7.9% and 13.6% [95% confidence interval (CI) = 13.5% to 13.6%], respectively, during the median follow-up of 8.6 years. The multivariable competing risk analysis suggested that older age at initial cancer diagnosis, white race, epithelial histologic subtypes of OC (serous, endometrioid, mucinous, and Brenner tumor), number of lymph nodes examined (<12), and radiotherapy were significantly associated with an elevated SPM risk. The DCA revealed that the net benefit obtained by our proposed model was higher than the all-screening or no-screening scenarios within a wide range of risk thresholds (1% to 23%). ConclusionThe competing risk nomogram can be potentially helpful for assisting physicians in identifying patients with different risks of SPMs and scheduling risk-adapted clinical management. More comprehensive data on treatment regimens and patient characteristics may help improve the predictability of the risk model for SPMs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available